Welcome to our dedicated page for INNOVATIVE INDUSTRIAL PROPERTIES SEC filings (Ticker: IIPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INNOVATIVE INDUSTRIAL PROPERTIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INNOVATIVE INDUSTRIAL PROPERTIES's regulatory disclosures and financial reporting.
Innovative Industrial Properties, Inc. subsidiary IIP Operating Partnership, LP entered into a Loan Agreement dated October 3, 2025 that provides a secured revolving credit facility with availability up to $100,000,000 and a maturity date of October 3, 2028. The facility includes a $35,000,000 accordion feature that can expand total capacity to $135,000,000 if lenders increase commitments.
Availability under the facility is subject to a borrowing base based on eligible investments and a receivable, and obligations are secured by substantial loan-party assets, including a revolving credit note from IQHQ, LP, Series G-1 cumulative redeemable preferred stock of IQHQ, Inc., and a corresponding warrant for common equity units of IQHQ Holdings, LP. The agreement requires a Debt Service Coverage Ratio of not less than 2.0 to 1.0, measured at each fiscal quarter end.
Innovative Industrial Properties, Inc. completed the initial closing of a previously announced preferred equity investment in IQHQ REIT on September 30, 2025 through its subsidiary IIP Life Science Investments LLC. The subsidiary purchased Series G-1 Preferred Stock at $1,000 per share for a total investment of approximately $5.0 million and received a warrant exercisable for common equity units equal to 1.5% of fully diluted IQHQ Holdings, LP. On the same date, IIP Life Science funded a committed loan of $100.0 million to IQHQ OP, bringing total funded amounts under the related reserve credit facility to $400.0 million. The Company also obtained a contractual right of first offer on certain IQHQ real estate assets. The report lists related agreements and a press release as exhibits and is signed by CFO David Smith.
Innovative Industrial Properties, through its operating partnership IIP OP, agreed to a multi-part strategic investment in IQHQ entities consisting of up to $170.0 million to purchase cumulative redeemable preferred stock and a $100.0 million committed lender role in a revolving credit facility. The preferred shares carry a 10.0% cash dividend and an initial 5.0% PIK dividend, with PIK step-ups and certain penalty mechanics tied to Trigger Events.
The transaction includes equity warrants (initial 1.5% and subsequent 3.5% coverage at $0.01 exercise price), a contractual right of first offer on IQHQ real estate sales, the right to appoint a voting director (intended to be CEO Paul Smithers), and customary closing conditions, timing limits and default/penalty provisions.
IIPR’s Q2-25 results show weakening fundamentals amid tenant stress. Rental revenue fell 21% YoY to $62.9 m as PharmaCann and other operators struggled, driving net income down 38% to $26.0 m and diluted EPS to $0.86 (vs $1.44).
Cash flow from operations remained positive at $102.7 m but slipped 24% YoY; cash on hand dropped to $99.7 m after funding $22.9 m of investments, repurchasing $20.1 m of common stock and paying $108.7 m in common dividends ($1.90/sh each quarter). Dividends now exceed cumulative earnings, pushing “dividends in excess of earnings” to –$264 m.
Balance-sheet leverage is modest (liabilities $425 m vs equity $1.88 b), yet the $291 m 5.5% notes maturing May 2026 loom large. Management admits current liquidity is insufficient and intends to refinance, assuming access to capital markets.
Tenant concentration remains high: top five operators generated 49% of rental revenue; PharmaCann defaulted in March, nullifying rent concessions, while two leases shifted to sales-type accounting with cash payments booked as deposits. An impairment of $3.5 m was recorded in Q1 and one California asset was sold for $1.8 m at book value.
The company issued 559 k Series A preferred shares via its ATM for $13.2 m and increased preferred outstanding to 1.56 m shares; early bond repayments of $8.8 m trimmed debt. Multiple securities-law class actions remain pending.